April 2019

Emerging Biotechnology Company Completes Registered Offering of Common Stock

United States - New York

Tyme Technologies Inc., an emerging biotechnology company developing cancer metabolism-based therapies, closed an underwritten registered offering on April 2, 2019, resulting in gross proceeds of approximately $12 million. Our firm represented Tyme in the offering.

Tyme registered the offering of 8 million shares of its common stock, par value $0.0001 per share, and of warrants to purchase 8 million shares of its common stock at a combined purchase price of $1.50 per share of common stock and accompanying warrant. Canaccord Genuity LLC acted as sole bookrunning manager for the offering and H.C. Wainwright & Co., LLC acted as lead manager.

Tyme’s shares trade on the NASDAQ Global Market under the symbol “TYME.”

The Faegre Drinker Biddle & Reath LLP website uses cookies to make your browsing experience as useful as possible. In order to have the full site experience, keep cookies enabled on your web browser. By browsing our site with cookies enabled, you are agreeing to their use. Review Faegre Drinker Biddle & Reath LLP's cookies information for more details.